<p>隨着美國股市在美聯儲決定降息後出現激增，投資者正在密切關注各個行業的潛在機會。雖然大盤股通常佔據頭條新聞，但便士股——通常是較小或較新的公司——由於其在穩健財務支持下可能帶來的顯著回報，仍然引起了人們的興趣。儘管被視為過去交易日的遺物，便士股仍為那些願意探索主流之外的投資者提供了引人入勝的前景，其中一些在當今市場環境中展現出令人印象深刻的資產負債表韌性和增長潛力。</p>
<h3>美國十大便士股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>回報與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$450.04M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.82</td>
<td>$632.91M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.93</td>
<td>$152.12M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.25</td>
<td>$545.17M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.37B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.51</td>
<td>$586.77M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>VAALCO Energy (EGY)</td>
<td>$3.53</td>
<td>$369.07M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8977</td>
<td>$6.36M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.20</td>
<td>$100.14M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股篩選器中的 343 只股票的完整列表。</p>
<p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
<h2>AirJoule Technologies (AIRJ)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> AirJoule Technologies Corporation 專注於大氣可再生能源和水收集技術，市值約為 1.784 億美元。</p>
<p><strong>運營：</strong> AirJoule Technologies 尚未報告任何具體的收入細分。</p>
<p><strong>市值：</strong> $178.4M</p>
<p>AirJoule Technologies 的市值為 1.784 億美元，尚未產生收入，專注於大氣可再生能源和水收集技術。儘管沒有債務，但公司的短期資產為 2790 萬美元，無法覆蓋其長期負債 8440 萬美元。董事會和管理層相對較新，平均任期為 1.8 年，表明有潛在的新戰略視角，但也缺乏經驗。最近的合作包括在德克薩斯州的 Nexus 數據中心進行的一項重要部署，依據水購買協議利用廢熱進行水生產，符合數據中心運營中的可持續發展趨勢。</p>
<ul>
<li>點擊探索我們在 AirJoule Technologies 財務健康報告中的詳細發現。</li>
<li>查看 AirJoule Technologies 的過去業績報告，以瞭解其在往年中的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis"/></p>
<p>AIRJ 財務狀況分析截至 2025 年 12 月</p>
<h2>AC Immune (ACIU)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> AC Immune SA 是一家臨牀階段的生物製藥公司，專注於發現、設計和開發與蛋白質錯誤摺疊相關的神經退行性疾病的藥物和診斷產品，市值為 2.7605 億美元。</p>
<p><strong>運營：</strong> 該公司通過發現和開發治療及診斷產品的細分市場產生收入，金額為 437 萬瑞士法郎。</p>
<p><strong>市值：</strong> $276.05M</p>
<p>AC Immune 的市值為 2.7605 億美元，作為一家尚未產生收入的公司，正在應對神經退行性疾病治療的挑戰。儘管其處於虧損狀態，並且最近的收入在 2025 年第三季度下降至 93.9 萬瑞士法郎，AC Immune 仍保持無債務狀態，並擁有超過一年的現金流。關於 ACI-7104.056 針對帕金森病的積極中期第二階段數據突顯了其管道的潛在進展。最近任命的臨牀諮詢委員會主席 Catherine Mummery 教授為該高風險領域的戰略發展提供了豐富的專業知識。</p>
<ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 AC Immune 的動態。</li>
<li>通過我們的公司收益預估報告，獲取對 AC Immune 前景和預期表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis"/></p>
<p>ACIU 財務狀況分析截至 2025 年 12 月</p>
<h2>Erasca (ERAS)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Erasca, Inc. 是一家臨牀階段的精準腫瘤學公司，致力於發現、開發和商業化針對 RAS/MAPK 通路驅動癌症的療法，市值約為 9.249 億美元。</p>
<p><strong>運營：</strong> Erasca, Inc. 目前未報告任何收入細分。</p>
<p><strong>市值：</strong> $924.9M</p>
<p>Erasca, Inc. 的市值約為 9.249 億美元，是一家尚未產生收入的臨牀階段精準腫瘤學公司，專注於 RAS/MAPK 通路驅動的癌症。該公司最近獲得了 ERAS-0015 的美國專利保護，推進了其 RAS 靶向產品線，ERAS-0015 和 ERAS-4001 均處於第一階段試驗中。儘管在 2025 年第三季度報告了 3060 萬美元的淨虧損，Erasca 仍保持無債務狀態，並持有 3.62 億美元的現金及現金等價物，為其提供了到 2028 年底的財務支持。經驗豐富的管理團隊和董事會支持公司在股價表現高度波動的情況下的戰略進展。</p>
<ul>
<li>點擊這裏瀏覽我們關於 Erasca 的全面資產負債表健康報告。</li>
<li>通過我們的詳細增長報告評估 Erasca 的未來收益預估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis"/></p>
<p>ERAS 財務狀況分析截至 2025 年 12 月</p>
<h2>接下來該如何做？</h2>
<ul>
<li>使用我們的篩選器深入瞭解所有 343 只美國便士股票。</li>
<li>想探索一些替代方案嗎？我們發現 12 只預計明年將支付超過 6% 股息收益率的美國股票。查看完整列表，免費獲取。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的完全自主塔。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

ERAS

ACIU

<p>這篇文章強調了在美國股市因降息而上漲的背景下，低價股的投資機會。文章介紹了 AirJoule Technologies、AC Immune 和 Erasca，詳細説明了它們的市值、財務健康狀況和戰略發展。AirJoule 專注於可再生能源，AC Immune 專注於神經退行性疾病，而 Erasca 則專注於腫瘤學。儘管面臨挑戰，這些公司在各自領域展現出增長和創新的潛力</p>

<p>As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are keenly observing potential opportunities across various sectors. While large-cap stocks often dominate headlines, penny stocks—typically smaller or newer companies—continue to pique interest due to their potential for significant returns when backed by solid financials. Despite being considered a relic of past trading days, penny stocks still offer intriguing prospects for those willing to explore beyond the mainstream, with some demonstrating impressive balance sheet resilience and growth potential in today's market landscape.</p>
<div class="lb-trans"><p>隨着美國股市在美聯儲決定降息後出現激增，投資者正在密切關注各個行業的潛在機會。雖然大盤股通常佔據頭條新聞，但便士股——通常是較小或較新的公司——由於其在穩健財務支持下可能帶來的顯著回報，仍然引起了人們的興趣。儘管被視為過去交易日的遺物，便士股仍為那些願意探索主流之外的投資者提供了引人入勝的前景，其中一些在當今市場環境中展現出令人印象深刻的資產負債表韌性和增長潛力。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$450.04M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.82</td>
<td>$632.91M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.93</td>
<td>$152.12M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.25</td>
<td>$545.17M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.37B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.51</td>
<td>$586.77M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>VAALCO Energy (EGY)</td>
<td>$3.53</td>
<td>$369.07M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8977</td>
<td>$6.36M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.20</td>
<td>$100.14M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>回報與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$450.04M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.82</td>
<td>$632.91M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.93</td>
<td>$152.12M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.25</td>
<td>$545.17M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.37B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.51</td>
<td>$586.77M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>VAALCO Energy (EGY)</td>
<td>$3.53</td>
<td>$369.07M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8977</td>
<td>$6.36M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.20</td>
<td>$100.14M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 343 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股篩選器中的 343 只股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
</div><h2>AirJoule Technologies (AIRJ)</h2>
<div class="lb-trans"><h2>AirJoule Technologies (AIRJ)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> AirJoule Technologies Corporation focuses on atmospheric renewable energy and water harvesting technologies, with a market cap of approximately $178.40 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> AirJoule Technologies Corporation 專注於大氣可再生能源和水收集技術，市值約為 1.784 億美元。</p>
</div><p><strong>Operations:</strong> AirJoule Technologies has not reported any specific revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> AirJoule Technologies 尚未報告任何具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> $178.4M</p>
<div class="lb-trans"><p><strong>市值：</strong> $178.4M</p>
</div><p>AirJoule Technologies, with a market cap of US$178.40 million, is pre-revenue and focuses on atmospheric renewable energy and water harvesting technologies. Despite having no debt, the company's short-term assets of US$27.9 million do not cover its long-term liabilities of US$84.4 million. The board and management are relatively new, with an average tenure of 1.8 years, indicating potential for fresh strategic perspectives but also a lack of experience. Recent collaborations include a significant deployment at Nexus Data Centers in Texas under a Water Purchase Agreement to leverage waste heat for water production, aligning with sustainability trends in data center operations.</p>
<div class="lb-trans"><p>AirJoule Technologies 的市值為 1.784 億美元，尚未產生收入，專注於大氣可再生能源和水收集技術。儘管沒有債務，但公司的短期資產為 2790 萬美元，無法覆蓋其長期負債 8440 萬美元。董事會和管理層相對較新，平均任期為 1.8 年，表明有潛在的新戰略視角，但也缺乏經驗。最近的合作包括在德克薩斯州的 Nexus 數據中心進行的一項重要部署，依據水購買協議利用廢熱進行水生產，符合數據中心運營中的可持續發展趨勢。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in AirJoule Technologies' financial health report.</li>
<li>Examine AirJoule Technologies' past performance report to understand how it has performed in prior years.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 AirJoule Technologies 財務健康報告中的詳細發現。</li>
<li>查看 AirJoule Technologies 的過去業績報告，以瞭解其在往年中的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis"/></p>
<p>AIRJ Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>AIRJ 財務狀況分析截至 2025 年 12 月</p>
</div><h2>AC Immune (ACIU)</h2>
<div class="lb-trans"><h2>AC Immune (ACIU)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $276.05 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> AC Immune SA 是一家臨牀階段的生物製藥公司，專注於發現、設計和開發與蛋白質錯誤摺疊相關的神經退行性疾病的藥物和診斷產品，市值為 2.7605 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its segment of discovering and developing therapeutic and diagnostic products, amounting to CHF 4.37 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過發現和開發治療及診斷產品的細分市場產生收入，金額為 437 萬瑞士法郎。</p>
</div><p><strong>Market Cap:</strong> $276.05M</p>
<div class="lb-trans"><p><strong>市值：</strong> $276.05M</p>
</div><p>AC Immune, with a market cap of $276.05 million, is navigating the challenging landscape of neurodegenerative disease treatment as a pre-revenue company. Despite its unprofitability and recent revenue decline to CHF 0.939 million for Q3 2025, AC Immune maintains a debt-free status and has sufficient cash runway for over a year. The positive interim Phase 2 data on ACI-7104.056 for Parkinson’s Disease highlights potential progress in its pipeline. The recent appointment of Prof. Catherine Mummery as Chairwoman of the Clinical Advisory Board brings seasoned expertise to guide strategic development in this high-risk sector.</p>
<div class="lb-trans"><p>AC Immune 的市值為 2.7605 億美元，作為一家尚未產生收入的公司，正在應對神經退行性疾病治療的挑戰。儘管其處於虧損狀態，並且最近的收入在 2025 年第三季度下降至 93.9 萬瑞士法郎，AC Immune 仍保持無債務狀態，並擁有超過一年的現金流。關於 ACI-7104.056 針對帕金森病的積極中期第二階段數據突顯了其管道的潛在進展。最近任命的臨牀諮詢委員會主席 Catherine Mummery 教授為該高風險領域的戰略發展提供了豐富的專業知識。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of AC Immune.</li>
<li>Gain insights into AC Immune's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 AC Immune 的動態。</li>
<li>通過我們的公司收益預估報告，獲取對 AC Immune 前景和預期表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis"/></p>
<p>ACIU Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>ACIU 財務狀況分析截至 2025 年 12 月</p>
</div><h2>Erasca (ERAS)</h2>
<div class="lb-trans"><h2>Erasca (ERAS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, with a market cap of approximately $924.90 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Erasca, Inc. 是一家臨牀階段的精準腫瘤學公司，致力於發現、開發和商業化針對 RAS/MAPK 通路驅動癌症的療法，市值約為 9.249 億美元。</p>
</div><p><strong>Operations:</strong> Erasca, Inc. currently does not report any revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> Erasca, Inc. 目前未報告任何收入細分。</p>
</div><p><strong>Market Cap:</strong> $924.9M</p>
<div class="lb-trans"><p><strong>市值：</strong> $924.9M</p>
</div><p>Erasca, Inc., with a market cap of approximately US$924.90 million, is a pre-revenue clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers. The company recently secured U.S. patent protection for ERAS-0015, advancing its RAS-targeting franchise with both ERAS-0015 and ERAS-4001 in Phase 1 trials. Despite reporting a net loss of US$30.6 million for Q3 2025, Erasca remains debt-free and holds US$362 million in cash and equivalents, providing financial runway into late 2028. The experienced management team and board support the company's strategic progression amid high volatility in share price performance.</p>
<div class="lb-trans"><p>Erasca, Inc. 的市值約為 9.249 億美元，是一家尚未產生收入的臨牀階段精準腫瘤學公司，專注於 RAS/MAPK 通路驅動的癌症。該公司最近獲得了 ERAS-0015 的美國專利保護，推進了其 RAS 靶向產品線，ERAS-0015 和 ERAS-4001 均處於第一階段試驗中。儘管在 2025 年第三季度報告了 3060 萬美元的淨虧損，Erasca 仍保持無債務狀態，並持有 3.62 億美元的現金及現金等價物，為其提供了到 2028 年底的財務支持。經驗豐富的管理團隊和董事會支持公司在股價表現高度波動的情況下的戰略進展。</p>
</div><ul>
<li>Navigate through the intricacies of Erasca with our comprehensive balance sheet health report here.</li>
<li>Assess Erasca's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瀏覽我們關於 Erasca 的全面資產負債表健康報告。</li>
<li>通過我們的詳細增長報告評估 Erasca 的未來收益預估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis"/></p>
<p>ERAS Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>ERAS 財務狀況分析截至 2025 年 12 月</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該如何做？</h2>
</div><ul>
<li>Get an in-depth perspective on all 343 US Penny Stocks by using our screener here.</li>
<li>Want To Explore Some Alternatives? We've found 12 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>使用我們的篩選器深入瞭解所有 343 只美國便士股票。</li>
<li>想探索一些替代方案嗎？我們發現 12 只預計明年將支付超過 6% 股息收益率的美國股票。查看完整列表，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的完全自主塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

發現投資機會：AirJoule Technologies 位列三隻有潛力的便士股之中